BofA Merrill Lynch,
bluebird bio anticipates the aggregate net proceeds from the offering
will be approximately
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was previously
filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing
potentially transformative gene therapies for severe genetic and orphan
diseases. bluebird bio has two clinical-stage programs in development.
The most advanced product candidate, Lenti-D, is in a recently-initiated
phase 2/3 study, the Starbeam Study, for the treatment of childhood
cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological
disorder affecting young boys. The next most advanced product candidate,
LentiGlobin, is currently in two phase 1/2 studies, one in the US (the
Northstar Study) and one in
bluebird bio also has an early-stage chimeric antigen receptor-modified
T cell (CAR-T) program for oncology in collaboration with
bluebird bio has operations in
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the terms, timing and completion of the proposed
offering; the use of proceeds of the offering; and bluebird bio’s
existing product candidates and research programs. Any forward-looking
statements are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, risk and uncertainties
related to market conditions and satisfaction of customary closing
conditions related to the proposed public offering, that the preliminary
results from our clinical trials will not continue or be repeated in our
ongoing clinical trials, the risk that previously conducted studies
involving similar product candidates will not be repeated or observed in
ongoing or future studies involving current product candidates, the risk
of cessation or delay of any of the ongoing or planned clinical studies
and/or our development of our product candidates, the risk of a delay in
the enrollment of patients in our clinical studies, the risk that our
Source: bluebird bio, Inc.
bluebird bio, Inc.
Richard E. T. Smith, Ph.D., 339-499-9382
Pure Communications, Inc.
Dan Budwick, 973-271-6085